biostudies-literatureUnknown8(7)Heudel P<h4>Importance</h4>Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy.<h4>Objective</h4>To evaluate the safety and efficacy of vistusertib in combination with anastrozole in the treatment of women with hormone receptor-positive recurrent or metastatic endometrial cancer.<h4>Design, settings, and participants</h4>The VICTORIA study was a multicenter, open-label, randomized clinical trial that accrued 75 patients with hormone receptor-positive recurrent or metastatic endometrial cancer from 12 cancer centers in France in April 2016 to October 2019. After a safety run-in period, a SiJAMA oncology1001-1009https://www.ebi.ac.uk/biostudies/studies/S-EPMC9100474biostudies-literatureSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.PMC9100474Marcel VArnaud APautier PDiaz JJFabbro MHeudel PChevalier-Place ATreilleux IBazan FDalban CAugereau PFrenel JSJoly FRay-Coquard IChakiba CPerol DAbdeddaim CYou BGarin GLancry-Lecomte LfalseSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.<h4>Importance</h4>Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy.<h4>Objective</h4>To evaluate the safety and efficacy of vistusertib in combination with anastrozole in the treatment of women with hormone receptor-positive recurrent or metastatic endometrial cancer.<h4>Design, settings, and participants</h4>The VICTORIA study was a multicenter, open-label, randomized clinical trial that accrued 75 patients with hormone receptor-positive recurrent or metastatic endometrial cancer from 12 cancer centers in France in April 2016 to October 2019. After a safety run-in period, a Si2022-01-01T00:00:00Z2022 Jul2026-05-09T22:15:43.808Z2024-11-13T01:35:14.598ZS-EPMC91004743555129910.1001/jamaoncol.2022.1047